Condition: Advanced Solid Tumors Harboring NTRK Fusion · Primary Central Nervous System Tumors Harboring NTRK Fusion · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
This description comes directly from the study's public registry record.
Ruihua Xu · 020-87343333 · xurh@sysucc.org.cn
Yuhong Li · liyh@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-Sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05745623